We really don't disagree, but I've been saying for some time they need to communicate more clearly. I don't know that they've had many other opportunities to communicate, but when they do, they aren't clear about what they are saying.

Perhaps their initial failure to communicate clearly resulted in an unwarranted rise to over $3, but they never really explained when if all goes right they'll be on the market with the cream or sublingual tablet. If you've ever invested in Biotech's you know it's unlikely that everything will go right, their will typically be delays, but I believe their unclear language had most of us convinced we'd have a cosmetic product on the market by July or earlier.

I would hope that the quarterly gives us a realistic view of where we're headed.

Gary